Cirrhosis Pathology — Causes and Consequences

Chronic Liver Injury → Hepatocellular Necrosis and Inflammation

• Persistent hepatotoxic insult (alcohol, HBV, HCV, autoimmune) causes repeated cycles of hepatocyte death via apoptosis and necrosis
• Inflammatory infiltrate (lymphocytes, macrophages) perpetuates tissue damage and activates innate immunity via pattern recognition receptors
• Repeated regeneration leads to replicative stress, telomere shortening, and eventual hepatocyte senescence
• Loss of normal hepatocyte mass triggers compensatory regeneration but ultimately cannot maintain synthetic function

Hepatic Stellate Cell (HSC) Activation and Fibrogenesis

• Damaged hepatocytes and activated Kupffer cells release pro-fibrogenic cytokines (TGF-β, PDGF, FGF)
• Quiescent HSCs (located in space of Disse) transdifferentiate into myofibroblasts via epithelial-mesenchymal transition (EMT)
• Activated HSCs undergo three critical changes: proliferation, contractility, and excessive extracellular matrix (ECM) production (collagen types I and III, fibronectin)
• Overproduction of tissue inhibitors of metalloproteinases (TIMPs) exceeds matrix metalloproteinase (MMP) activity, preventing remodeling and degradation
• Progressive accumulation of fibrosis within portal areas extends bridging fibrosis connecting portal tracts to central veins (bridging fibrosis), eventually encircling hepatocyte nodules

Progressive Architectural Distortion and Nodule Formation

• Fibrous septa partition the liver into regenerative nodules separated by bands of fibrous tissue
• Micronodular cirrhosis (<3 mm): nodules composed of 1-2 hepatocyte layers; classically associated with alcohol
• Macronodular cirrhosis (>3 mm): larger nodules with preserved acinar structure; associated with viral hepatitis, NAFLD
• Loss of normal relationships between central vein, portal triads, and hepatocyte plates destroys the sinusoidal architecture and normal metabolic orientation
• Nodules become autonomous regenerative units lacking normal growth regulation (loss of HNF4α and other transcriptional regulators)

Portal Hypertension Development

• Fibrous septa and nodular regeneration increase intrahepatic resistance to portal blood flow (mechanical obstruction)
• Activated HSCs and myofibroblasts increase vasoconstriction through decreased endothelial nitric oxide synthase (eNOS) activity and increased endothelin-1 (ET-1) production
• Sinusoidal capillarization: loss of fenestration in sinusoidal endothelium and increased basement membrane deposition impair nutrient and oxygen exchange
• Endothelial dysfunction reduces eNOS-derived vasodilatory nitric oxide (NO), shifting balance toward vasoconstriction
• Systemic vasodilation paradoxically worsens portal hypertension through decreased peripheral vascular resistance and increased cardiac output (compensatory mechanism via activation of renin-angiotensin-aldosterone system [RAAS] and sympathetic nervous system)
• Portal pressure elevation (normal <5 mmHg; clinically significant >12 mmHg) drives formation of portosystemic collaterals (esophageal varices, hemorrhoids, caput medusae, retroperitoneal shunts)

Hepatic Insufficiency and Synthetic Dysfunction

• Progressive hepatocyte loss reduces synthesis of albumin, prothrombin complex factors (II, VII, IX, X), and clotting factors V, VIII, fibrinogen, and platelets
• Impaired metabolism of ammonia via urea cycle produces hyperammonemia contributing to hepatic encephalopathy (ammonia crosses blood-brain barrier, increases astrocyte glutamine production, alters neurotransmitter metabolism)
• Loss of detoxification capacity for endotoxin, bile acids, and other gut-derived toxins due to reduced first-pass hepatic metabolism
• Decreased production of thrombopoietin and platelet sequestration in enlarged spleen causes thrombocytopenia
• Impaired bilirubin conjugation and excretion despite hepatocyte regeneration leads to cholestasis and jaundice

Immune Dysfunction and Infection Susceptibility

• Kupffer cell dysfunction impairs opsonization and clearance of gut-derived bacteria
• Reduced synthesis of complement components, opsonins, and immunoglobulins (especially IgM)
• Disruption of natural barrier function and bacterial translocation from portal circulation bypass hepatic filtration via portosystemic shunts
• Increased risk of spontaneous bacterial peritonitis (SBP), hepatic encephalopathy, and sepsis

Alcohol-Related Liver Disease (ARLD)

• Most common cause of cirrhosis in Western countries; accounts for 40-50% of cases in US
• Dose-dependent injury with threshold approximately ≥40 g/day in men, ≥20 g/day in women for 10+ years
• Mechanisms: alcohol metabolite acetaldehyde induces oxidative stress via CYP2E1, microbial translocation and LPS-TLR4 signaling, magnesium depletion
• Histology progression: steatosis → alcoholic hepatitis (ballooned hepatocytes, Mallory-Denk bodies, neutrophilic infiltrate) → cirrhosis (predominantly micronodular)

Viral Hepatitis

• Hepatitis C Virus (HCV): causes cirrhosis in 10-20% of chronically infected; HCV core protein activates TGF-β signaling; mixed cryoglobulinemia associated with HCV
• Hepatitis B Virus (HBV): 5-10% of adults develop chronic HBV; HBV-X protein and surface antigen drive fibrosis; increased risk of hepatocellular carcinoma (HCC)
• Hepatitis D Virus (HDV): requires HBV coinfection; more aggressive fibrosis progression than HBV alone
• Persistent viral replication and chronic inflammation drive progressive fibrosis; viral genotype and immune response influence progression rate

Non-Alcoholic Fatty Liver Disease (NAFLD) / NASH

• Rapidly increasing cause of cirrhosis; up to 30% of Western population has NAFLD
• NASH (Non-Alcoholic SteatoHepatitis): subset with inflammation and hepatocellular injury; lipotoxicity and ROS generation from mitochondrial dysfunction drive fibrosis
• Risk factors: obesity, metabolic syndrome (insulin resistance, hyperglycemia, dyslipidemia), T2DM
• Two-hit hypothesis: initial steatosis from impaired fatty acid oxidation and increased de novo lipogenesis; second hit from oxidative stress, ER stress, mitochondrial dysfunction causing inflammation
• Histology: macrovesicular steatosis, hepatocellular ballooning, Mallory-Denk bodies (may be absent), progression to macronodular cirrhosis

Autoimmune Hepatitis (AIH)

• Mediated by CD8+ T cells targeting hepatocyte antigens (autosomal recessive transporter gene product SLC44A1)
• More common in women; associated with other autoimmune conditions
• Presents with interface hepatitis (inflammation at portal-hepatocyte boundary); bridging necrosis
• Marked elevation of transaminases and immunoglobulins (especially IgG)
• Responds to immunosuppression; cirrhosis develops in 40-50% without treatment

Primary Biliary Cholangitis (PBC)

• Cholestatic cirrhosis with destruction of small intrahepatic bile ducts
• Autoimmune condition; 90% women; anti-mitochondrial antibody (AMA) positive
• Histology: lymphocytic infiltration of bile ducts, bile duct loss, granuloma formation (in early stages)
• Progression to cirrhosis with bile duct disappearance and cholestasis

Primary Sclerosing Cholangitis (PSC)

• Progressive inflammatory fibrosis of extrahepatic and intrahepatic bile ducts; often hilar stricturing
• Strong association with inflammatory bowel disease (IBD); T-cell mediated autoimmune destruction
• Histology: "onion-skinning" of bile ducts with concentric fibrosis
• Increased risk of cholangiocarcinoma; intrahepatic cirrhosis develops from secondary biliary obstruction

Hemochromatosis (Hereditary Iron Overload)

• HFE gene mutations (C282Y homozygote, ~85% of genetic hemochromatosis)
• Progressive iron deposition in hepatocytes → cirrhosis with iron in hepatocytes (Prussian blue positive)
• Secondary mechanism: iron-catalyzed oxidative stress via Fenton reaction
• Iron also deposits in pancreas (diabetes), heart (cardiomyopathy), joints (arthropathy)

Wilson Disease (Copper Overload)

• Autosomal recessive defect in ATP7B gene (copper-transporting ATPase); impaired ceruloplasmin synthesis and biliary copper excretion
• Hepatic copper accumulation causes hepatotoxicity; deposits visible on rhodanine stain
• Kayser-Fleischer rings (copper in Descemet membrane of cornea) pathognomonic
• Can present with acute hepatitis or fulminant hepatic failure, or chronic cirrhosis
• Treatable with chelation if caught early

Biliary Cirrhosis (Secondary)

• Chronic obstruction of bile flow (gallstones, strictures, tumors) or bile duct destruction
• Progressive cholestasis → bile acid accumulation → hepatocyte injury and fibrosis
• Histology: bile duct proliferation at portal tracts, cholestasis (bile plugs in canaliculi), eventual cirrhosis with bridging fibrosis

Cystic Fibrosis-Related Liver Disease

• CFTR mutation causes impaired bile composition; cholestasis and increased vulnerability to bile salt toxicity
• Progressive portal tract inflammation → cirrhosis in 5-10% of CF patients
• Focal biliary cirrhosis (limited to some regions) progresses to multilobular involvement

Indian Childhood Cirrhosis (ICC) / Neonatal Sclerosing Cholangitis

• Environmental copper overload (historically from copper vessels and contaminated water)
• Genetic susceptibility to copper accumulation
• Now rare with improved water quality and reduced copper exposure

Miscellaneous Causes

• α1-Antitrypsin deficiency: glycoprotein accumulation in hepatocyte ER (seen with PAS-positive, diastase-resistant globules); predisposes to emphysema and cirrhosis
• Budd-Chiari syndrome: thrombosis of hepatic veins → acute fulminant hepatitis or chronic congestion and cirrhosis
• Hepatoportal sclerosis: idiopathic obliteration of portal vein branches
• Steatohepatitis from drugs: methotrexate, tetracyclines, amiodarone, total parenteral nutrition
• Schistosomiasis: Schistosoma mansoni eggs deposit in portal tracts → granulomatous inflammation and fibrosis (pipe stem fibrosis)

Hepatic Insufficiency Manifestations

• Jaundice: yellowing of skin/sclera from hyperbilirubinemia (direct + indirect); reflects both impaired conjugation and cholestasis
• Coagulopathy: prolonged PT/INR from reduced factors II, V, VII, X, fibrinogen; hemorrhagic tendency (epistaxis, GI bleeding, easy bruising)
• Hypoalbuminemia: reduced serum albumin <3.0 g/dL; manifests as ascites (osmotic effect, increased capillary filtration), edema, and oncotic pressure loss
• Hepatic encephalopathy: acute or chronic neuropsychiatric dysfunction from hyperammonemia and other neurotoxins; asterixis ("flapping tremor"), confusion, personality changes, sleep-wake reversal; can progress to coma
• Hepatorenal syndrome (HRS): progressive renal vasoconstriction despite splanchnic vasodilation; functional renal failure with elevated creatinine despite preserved kidney histology (prerenal azotemia)
• Bleeding tendency: thrombocytopenia from splenic sequestration (splenomegaly) and reduced TPO; reduced clotting factor synthesis; dysfibrinogenemia from abnormal fibrinogen glycosylation
• Feminization signs: gynecomastia, testicular atrophy, female distribution of body hair; from impaired estrogen metabolism (aromatase activity in adipose tissue unopposed by hepatic inactivation)
• Spider angiomas: clusters of dilated capillaries on chest/face; reflect estrogen-induced angiogenesis and portal hypertension

Portal Hypertension Manifestations

• Esophageal varices: dilated veins in distal esophagus and gastroesophageal junction; prone to rupture (life-threatening GI hemorrhage); seen on endoscopy as tortuous blue vessels
• Caput medusae: visibly dilated, tortuous superficial abdominal veins radiating from umbilicus; from recanalization of paraumbilical veins and portal-umbilical anastomoses
• Hemorrhoids: internal hemorrhoids from portal-systemic collateralization via superior/middle/inferior rectal vessels
• Ascites: fluid accumulation in peritoneal cavity; results from combined portal hypertension (increased hydrostatic pressure), hypoalbuminemia (reduced oncotic pressure), renal sodium retention (RAAS activation), and lymphatic obstruction; initially transudate with protein <2.5 g/dL, serum-ascites albumin gradient (SAAG) >1.1 g/dL (portal hypertension mechanism)
• Splenomegaly: congestion from portal hypertension; can be massive; contributes to thrombocytopenia
• Hepatic encephalopathy: worsened by portal-systemic shunting of ammonia and other toxins that bypass hepatic detoxification

Infectious Complications

• Spontaneous bacterial peritonitis (SBP): infection of ascitic fluid without perforation; presents with abdominal pain, fever, worsening encephalopathy; ascitic fluid with >250 PMNs/μL and positive culture
• Bacterial translocation: gut bacteria cross intestinal barrier and portal-systemic shunts escape hepatic clearance

Metabolic Manifestations

• Hepatic osteoporosis: from cholestasis (malabsorption of fat-soluble vitamins), reduced physical activity, hypogonadism
• Bleeding from GI varices: hematemesis, melena; presents with hemodynamic instability

Physical Examination Findings Correlating to Pathology

• Hepatomegaly (early) then hepatic shrinkage (advanced): reflects regenerative nodules initially, then progressive parenchymal loss
• Firm, irregular liver edge: fibrosis and nodularity on palpation
• Splenomegaly: congestion from portal hypertension
• Ascites: fluid wave, dullness to percussion; from mechanisms above
• Palmar erythema: hyperemic thenar/hypothenar emin

Initial laboratory clues

• Thrombocytopenia: often the earliest and most sensitive routine lab abnormality, reflecting splenic sequestration and low thrombopoietin — precedes hypoalbuminemia and INR elevation
• Synthetic dysfunction panel: low albumin, prolonged INR, and hyperbilirubinemia indicate decompensation, not merely fibrosis; aminotransferases are often normal or only mildly elevated in established cirrhosis
• AST:ALT ratio >2:1 with modest absolute elevations suggests alcohol-related injury (pyridoxine-dependent ALT synthesis is impaired)
• Etiologic workup (AASLD): hepatitis B and C serologies, iron studies with ferritin/transferrin saturation, ceruloplasmin in patients under ~40, alpha-1 antitrypsin level and phenotype, AMA, ANA/anti–smooth muscle antibody with IgG

Noninvasive fibrosis assessment (first-line)

• FIB-4 index (age, AST, ALT, platelets): validated first-tier screen, especially in NAFLD/MASLD pathways
• Transient elastography (VCTE, FibroScan) measures liver stiffness; high stiffness values support cirrhosis and are used with platelet count in the Baveno VII criteria to rule out clinically significant portal hypertension and defer screening endoscopy
• Ultrasound: nodular surface contour, caudate lobe hypertrophy, splenomegaly, recanalized paraumbilical vein, portal flow reversal

Confirmatory testing

• Liver biopsy remains the histologic gold standard — diffuse regenerative nodules encircled by fibrous septa — but is reserved for diagnostic uncertainty or overlapping etiologies
• Hepatic venous pressure gradient (HVPG): normal ≤5 mmHg; clinically significant portal hypertension ≥10 mmHg (threshold for varix formation); variceal bleeding risk rises above 12 mmHg
• Diagnostic paracentesis in any new ascites: SAAG ≥1.1 g/dL establishes portal hypertension; ascitic total protein <2.5 g/dL distinguishes cirrhosis from cardiac ascites

Severity scoring

• Child–Turcotte–Pugh: bilirubin, albumin, INR, ascites, encephalopathy → classes A/B/C, predicts perioperative risk
• MELD 3.0 (bilirubin, INR, creatinine, sodium, albumin, sex) drives OPTN/UNOS transplant allocation in the United States
• AASLD recommends surveillance ultrasound with or without AFP every 6 months for hepatocellular carcinoma once cirrhosis is established

Treat the underlying cause — the only intervention that can regress fibrosis

• Direct-acting antivirals (e.g., sofosbuvir-based regimens) for HCV and nucleos(t)ide analogues (entecavir, tenofovir) for HBV, per AASLD guidance
• Alcohol abstinence with pharmacotherapy for alcohol use disorder; weight loss and metabolic control for MASLD/NASH
• Vaccination against hepatitis A and B, influenza, pneumococcus (CDC/ACIP)

Ascites (AASLD)

• Sodium restriction plus aldosterone antagonist + loop diuretic: spironolactone with furosemide, classically in a 100:40 mg ratio to maintain potassium balance
• Large-volume paracentesis with IV albumin for tense ascites (albumin replacement when >5 L is removed prevents post-paracentesis circulatory dysfunction)
• TIPS for refractory ascites; liver transplantation is definitive

Varices (AASLD / Baveno VII)

• Nonselective beta blockers: carvedilol is preferred for primary prophylaxis because it adds anti–alpha-1 splanchnic vasodilator effect; endoscopic variceal ligation where beta blockers are not tolerated
• Acute bleeding is an emergency: resuscitate with restrictive transfusion, start a splanchnic vasoconstrictor (octreotide) and prophylactic ceftriaxone, then urgent EVL; balloon tamponade or early/rescue TIPS if bleeding persists

Avoid

• NSAIDs — blunt renal prostaglandins and precipitate HRS
• Aminoglycosides, and benzodiazepines/opioids which precipitate encephalopathy
• Prophylactic FFP for an elevated INR — hemostasis is rebalanced, and INR does not predict bleeding
• Protein restriction in encephalopathy, which worsens sarcopenia

Portal hypertension–driven (mechanism: collateral formation and splanchnic vasodilation)

• Variceal hemorrhage — emergency: rupture of submucosal gastroesophageal collaterals; signaled by hematemesis or melena with hemodynamic instability; mortality is highest in the first days after the bleed
• Ascites and hepatic hydrothorax: hydrostatic and oncotic imbalance with RAAS-driven sodium retention; hydrothorax arises from diaphragmatic defects and is typically right-sided
• Portal vein thrombosis: stagnant flow plus rebalanced hemostasis; suspect with sudden ascites, worsening encephalopathy, or bleeding

Infectious and renal

• Spontaneous bacterial peritonitis — emergency: bacterial translocation with impaired Kupffer clearance; ascitic PMN ≥250/µL is diagnostic even with negative culture
• Hepatorenal syndrome — emergency: extreme splanchnic vasodilation → renal vasoconstriction; rising creatinine with bland urine sediment, urine sodium markedly low, and no response to volume challenge

Neuro, pulmonary, and cardiac

• Hepatic encephalopathy: portosystemic shunting of ammonia → astrocyte glutamine accumulation and cerebral edema; asterixis
• Hepatopulmonary syndrome: intrapulmonary vascular dilatation → shunt physiology; platypnea–orthodeoxia (dyspnea and desaturation worse when upright)
• Portopulmonary hypertension: true pulmonary arterial remodeling; a severe elevation in pulmonary pressures contraindicates transplant until treated
• Cirrhotic cardiomyopathy: blunted contractile reserve unmasked by stress or TIPS

Malignancy

• Hepatocellular carcinoma: regenerative nodules with unregulated proliferation; signaled by a new arterially enhancing lesion with washout or a rising AFP — the reason AASLD mandates 6-month surveillance

Treatment-related

• TIPS: diverts ammonia-rich blood past hepatocytes → new or worsened encephalopathy, and volume loading can precipitate heart failure
• Diuretics: hyponatremia, AKI, hyperkalemia and gynecomastia with spironolactone
• Lactulose: overdiuresis of the gut with dehydration and hypernatremia
• Post-paracentesis circulatory dysfunction when albumin is omitted after large-volume removal
• Post-EVL ulceration or stricture

• New or worsening ascites → diagnostic paracentesis is always the single best next step: compute the SAAG. SAAG ≥1.1 g/dL means portal hypertension; ascitic protein <2.5 g/dL then separates cirrhosis (low) from cardiac ascites (high). Do not start diuretics before tapping.
• Ascitic PMN ≥250/µL diagnoses SBP regardless of culture; a polymicrobial culture with multiple organisms, low glucose, and high LDH points instead to secondary bacterial peritonitis requiring imaging and surgery — the classic distractor.
• Thrombocytopenia is the earliest routine lab hint of cirrhosis, from hypersplenism plus low thrombopoietin — examiners love an isolated low platelet count in a patient with risk factors.
• AST:ALT >2:1 with values in the hundreds, Mallory–Denk bodies, and micronodular cirrhosis = alcohol. Viral hepatitis and MASLD tend toward macronodular.
• Do not transfuse FFP for an elevated INR alone. Cirrhotic hemostasis is rebalanced — procoagulant and anticoagulant factors fall together (protein C, antithrombin), which is also why portal vein thrombosis occurs despite a prolonged INR.
• Carvedilol is the preferred nonselective beta blocker for primary prophylaxis of variceal bleeding (Baveno VII); in acute bleeding the answer set is octreotide + prophylactic ceftriaxone + endoscopic band ligation, and the antibiotic is what improves survival independent of the endoscopy.
• Lactulose, not protein restriction, for hepatic encephalopathy; add rifaximin for recurrence. A normal ammonia level does not exclude HE and a high level does not diagnose it — HE is clinical.
• HCC surveillance is ultrasound every 6 months in all cirrhotics (AASLD), including those cured of HCV — the common trap is assuming SVR removes cancer risk.
• MELD 3.0 drives transplant allocation; Child–Turcotte–Pugh is the score used to estimate perioperative mortality for non-transplant surgery.